This study is testing a new drug called IM-1021 for people with advanced cancer. The drug is an antibody-drug conjugate (ADC), meaning it links antibodies, which are proteins that can target cancer cells, with a drug to kill them. The study has two parts: Part A tests different doses to find the safest one, and Part B checks how well the safe dose works. The drug is given through an IV (intravenous), which is a needle in a vein.

People can join if they have certain types of cancer, like some lymphomas (cancers of the lymphatic system) or solid tumors in organs like the pancreas or lungs, and meet specific health criteria. They must be 18 or older and have tried other treatments first. Some health conditions, like active brain disease or prior treatment with similar drugs, may prevent participation.

• The study involves receiving the drug through an IV and may require multiple visits.
• Participants must have tried other treatments first and have certain cancers.
• There may be risks, such as side effects, but the study aims to find a safe dose.